跳转至内容
Merck
CN

07-631

Anti-cdk2 Antibody

Upstate®, from rabbit

别名:

Anti-CDKN2, Anti-p33(CDK2)

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
polyclonal
Application:
IP, WB
Citations:
18
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


biological source

rabbit

Quality Level

conjugate

unconjugated

antibody form

purified antibody

antibody product type

primary antibodies

clone

polyclonal

species reactivity

human

manufacturer/tradename

Upstate®

technique(s)

immunoprecipitation (IP): suitable, western blot: suitable

isotype

IgG

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... CDK2AP1(8099)

General description

33 kDa

Immunogen

peptide corresponding to amino acids 287-298 (C-QDVTKPVPHLRL) of human cdk2

Application

Anti-cdk2 Antibody is a high quality Rabbit Polyclonal Antibody for the detection of cdk2 & has been validated in IP & WB.

Biochem/physiol Actions

Predicted to cross-react with mouse, rat, non-human primates, and hamster based on sequence homology
Recognizes human p33cdk2 protein kinase.

Physical form

Format: Purified

Analysis Note

Control
Colon tissue
routinely evaluated by immunoblot in nuclear extracts from HeLa cells

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany


Still not finding the right product?

试用我们的 产品选型工具 工具缩小选择范围


存储类别

10 - Combustible liquids

wgk

WGK 1



分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Sublytic complement attack induces cell cycle in oligodendrocytes.
Rus, H G, et al.
Journal of immunology (Baltimore, Md. : 1950), 156, 4892-4900 (1996)
Carlotta Costa et al.
Cancer discovery, 10(1), 72-85 (2019-10-09)
The combination of CDK4/6 inhibitors with antiestrogen therapies significantly improves clinical outcomes in ER-positive advanced breast cancer. To identify mechanisms of acquired resistance, we analyzed serial biopsies and rapid autopsies from patients treated with the combination of the CDK4/6 inhibitor
C S Rani et al.
The Journal of biological chemistry, 272(16), 10777-10783 (1997-04-18)
Platelet-derived growth factor (PDGF) and serum, but not epidermal growth factor (EGF), stimulated sphingosine kinase activity in Swiss 3T3 fibroblasts and increased intracellular concentrations of sphingosine 1-phosphate (SPP), a sphingolipid second messenger (Olivera, A., and Spiegel, S. (1993) Nature 365